ArticleFrontiers in genetics2026
When genomics companies act as biobanks: governance challenges in an era of genomic assetization.
Article in Frontiers in genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Navigating the human gene editing scene and proposing a new governance framework in Africa: from knowledge to policy to action.Frontiers in genome editing · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Contemporary genomics companies increasingly perform core biobanking functions-collecting, storing, and sharing large volumes of genetic data and biospecimens-without being widely recognized or governed as biobanks. At the same time, these holdings are increasingly undergoing assetization: the treatment of genomic data and biospecimens as corporate assets subject to sale, acquisition, and valuation as indicators of company worth. This paper examines governance challenges arising from this transformation, particularly when companies experience restructuring, acquisition, or insolvency. Methods: Using a comparative qualitative case study approach, the paper analyzes three examples: a Nigerian genomics company created to expand African representation in genomics, DNA marketplaces that aggregate and license genetic data, and recent events surrounding the attempted sale of 23andMe's genomic holdings. The analysis draws on scholarship on biobanking governance, commercialization in biomedicine, and justice-oriented critiques of genomic research. Results: The paper identifies governance issues that have emerged as biobanking technologies and organizational forms have evolved. Commercial genomics infrastructures expose gaps in existing biobanking governance, regarding the way data and samples are stewarded during organizational change, oversight of financial pressures in custodial decision-making, participation incentivizes, and public understandings of biobanking that are shaped by consumer and other commercial genomics infrastructures. Discussion: These findings highlight the need for governance approaches that better reflect todays interconnected biobanking ecosystem, which includes public and nonprofit biobanks, government-academic-industry collaborations, and companies operating as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.